{
    "2021-09-09": [
        [
            {
                "time": "",
                "original_text": "参与康美药业重组？康泰生物：不存在！",
                "features": {
                    "keywords": [
                        "康美药业",
                        "重组",
                        "康泰生物"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "康泰生物：不存在康美药业与公司洽谈重组的情形",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "康美药业",
                        "重组",
                        "洽谈"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "康泰生物(300601)2021年半年报点评：业绩实现增长 13价肺炎疫苗即将上市",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "半年报",
                        "业绩增长",
                        "13价肺炎疫苗",
                        "上市"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "疫苗板块2021H1总结：新冠疫苗商业化价值初现 在研管线亮点颇多",
                "features": {
                    "keywords": [
                        "疫苗板块",
                        "新冠疫苗",
                        "商业化",
                        "在研管线"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}